A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT01205373
- Locations
- πΊπΈ
1268.7.001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States
Comprehensive Add on Study in Japan
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 574
- Registration Number
- NCT01204294
- Locations
- π―π΅
1218.78.037 Boehringer Ingelheim Investigational Site, Higashi Osaka, Osaka, Japan
π―π΅1218.78.026 Boehringer Ingelheim Investigational Site, Kasugai, Aichi, Japan
π―π΅1218.78.038 Boehringer Ingelheim Investigational Site, Kawachinagano, Osaka, Japan
Telmisartan+Amlodipine Fixed Dose Combination in Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: telmisartan+amlodipine fixed dose combination
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27
- Registration Number
- NCT01204398
- Locations
- π¨π³
1235.31.86001 Boehringer Ingelheim Investigational Site, Shanghai, China
Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT01195675
- Locations
- π©πͺ
1245.16.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects
- Conditions
- Healthy
- Interventions
- Drug: BI 638683 or placeboDrug: Placebo solution
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT01195688
- Locations
- π©πͺ
1279.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 234
- Registration Number
- NCT01194830
- Locations
- πΊπΈ
1218.75.053 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
πΊπΈ1218.75.102 Boehringer Ingelheim Investigational Site, Tomball, Texas, United States
πΊπΈ1218.75.037 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 547
- Registration Number
- NCT01193218
- Locations
- π―π΅
1245.38.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo, Japan
π―π΅1245.38.032 Boehringer Ingelheim Investigational Site, Okawa, Fukuoka, Japan
π―π΅1245.38.012 Boehringer Ingelheim Investigational Site, Sasima-gun, Ibaraki, Japan
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 475
- Registration Number
- NCT01191944
- Locations
- π¨π³
248.671.86013 Boehringer Ingelheim Investigational Site, Chongqing, China
π¨π³248.671.86012 Boehringer Ingelheim Investigational Site, Chengdu, China
π¨π³248.671.86014 Boehringer Ingelheim Investigational Site, Chongqing, China
Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01189175
- Locations
- π©πͺ
1272.5.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT01189201
- Locations
- π©πͺ
1275.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany